Antares Pharma (NASDAQ:ATRS) was downgraded by investment analysts at TheStreet from a “hold” rating to a “sell” rating in a note issued to investors on Monday, ARN reports. Antares Pharma Inc (NASDAQ:ATRS), shares after opening at $2.98 moved to $3.06 on last trade day and at the end of the day closed at $2.91. Company price to sales ratio in past twelve months was calculated as 18.35 and price to cash ratio as 5.99. Antares Pharma Inc (NASDAQ:ATRS), showed a negative weekly performance of 11.0%.
Stock analysts at Jefferies Group reduced their price target on shares of Zoetis (NYSE:ZTS) to $34.00 in a report issued on Monday, AnalystRatings.Net reports. Jefferies Group’s price objective points to a potential upside of 19.72% from the company’s current price. Zoetis Inc (NYSE:ZTS), shares advanced 0.25% in last trading session and ended the day on $28.55. Zoetis Inc (NYSE:ZTS), return on equity ratio is recorded as 61.20% and its return on assets is 8.00%. Zoetis Inc (NYSE:ZTS), yearly performance is -13.30%.
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by Zacksfrom a “neutral” rating to an “underperform” rating in a research note issued on Tuesday, Analyst Ratings News reports. They currently have a $2.40 price target on the stock. Zacks‘s price objective suggests a potential downside of 6.61% from the company’s current price. Amicus Therapeutics, Inc. (NASDAQ:FOLD), shares moved down 8.00% in last trading session and was closed at $1.84, while trading in range of $ 1.80 – 1.95. Amicus Therapeutics, Inc. (NASDAQ:FOLD), year to date (YTD) performance is -21.70%.
ImmunoGen, Inc. (NASDAQ:IMGN), shares have been up over a couple of trading sessions following the company’s announcement of encouraging initial results on its oncology candidate, IMGN853, on Apr 8. The stock has gained over 8% since the announcement. ImmunoGen, Inc. (NASDAQ:IMGN), weekly performance is -7.51%. On last trading day company shares ended up $12.80. ImmunoGen, Inc. (NASDAQ:IMGN), distance from 50-day simple moving average (SMA50) is -17.58%. Analysts mean target Price for the company is $16.95.
Leave a Reply